Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0899 • ACR Convergence 2022
Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis
Joan Manuel Dapeña, Lucia Alascio, Eliana Rebeca Serrano, Juan Manuel Bande, Maria Alejandra Medina, Diana Silvia Klajn, Jose Angel Caracciolo and Silvia Beatriz Papasidero, Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina
Background/Purpose: Multiple questionnaires and objective assessment tools have been developed to determine functional compromise in Rheumatoid Arthritis (RA). One of the most used tools to…
Abstract Number: 0915 • ACR Convergence 2022
Methotrexate Therapy Results in Disparate Methotrexate Polyglutamate Profiles in Peripheral Blood Mononuclear Cells Compared with Erythrocytes
Renske Hebing¹, Marry Lin², Sohaila Mahmoud³, Ittai B. Muller², Sandra Heil⁴, Pieter Griffioen⁴, Eduard A. Struys², Willem Lems⁵, Bart van den Bemt⁶, Michael Nurmohamed⁷, Gerrit Jansen⁸ and Robert De Jonge⁹, ¹Amsterdam Rheumatology and immunology Center, Amsterdam UMC – location Reade, Amsterdam, Netherlands, ²Department of Clinical Chemistry, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, ⁴Department of Clinical Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁵Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁶Department of Pharmacy, Sint Maartenskliniek, Ubbergen, Netherlands, ⁷Amsterdam University Medical Center, Kortenhoef, Netherlands, ⁸Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ⁹Department of Clinical Chemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Analyses of methotrexate polyglutamates (MTX-PGs) in red blood cells (RBCs) has been employed as tool for personalized therapy approach for RA patients during MTX…
Abstract Number: 0931 • ACR Convergence 2022
Rituximab versus Leflunomide in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis Despite Methotrexate Treatment- an Open Label Randomized Controlled Trial
Rashmi Roongta¹, Geetabali Sircar¹, Parasar Ghosh², Dipendranath Ghosh¹ and Hiramanik Sit¹, ¹Institute of Postgraduate Medical Education and Research, Kolkata, West Bengal, India, ²Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India
Background/Purpose: Active rheumatoid arthritis (RA) despite methotrexate (MTX) monotherapy is seen in about 40-50% of patients1. The current ACR guidelines recommend adding a biologic or…
Abstract Number: 1123 • ACR Convergence 2022
Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
Pierre-Antoine Juge¹, Steven Gazal², Raphaël Borie³, Lidwine Wemeau⁴, Marie-Pierre Debray⁵, Sebastien Ottaviani⁶, Sylvain Marchand Adam⁷, Christophe Richez⁸, Hilario Nunes⁹, Pascal Richette¹⁰, Caroline Kannengiesser¹¹, Jérome Avouac¹², Jean Sibilia¹³, René-Marc Flipo¹⁴, Vincent Cottin¹⁵, Thierry Schaeverbeke¹⁶, Martin Soubrier¹⁷, Nathalie Saidenberg-Kermanac’h¹⁸, Dominique Valeyre¹⁹, Catherine Boileau¹¹, Bruno Crestani²⁰ and Philippe Dieude²¹, ¹Rheumatology department, Bichat Hospital, Paris, France, ²University of Southern California, Los Angeles, CA, ³Pulmonology department, Bichat Hospital, Paris, France, ⁴Pulmonology department, Lille University hospital, Lille, France, ⁵Radiology department, Hôpital Bichat, Paris, France, ⁶Hopital Bichat-Claude Bernard, Paris, France, ⁷Pulmonology department, Tours University Hospital, Tours, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Pulmonology department, Hopital Avicenne, Bobigny, France, ¹⁰Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹¹Genetic Department, Bichat hospital, Paris, France, ¹²Rheumatology Department, Cochin hospital, Paris, France, ¹³University Hospital of Strasbourg, Strasbourg, France, ¹⁴Hôpital Roger Salengro, Lille, France, ¹⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁶FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, Bordeaux, France, ¹⁷Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁸Rheumatology Department, Avicenne Hospital, Bobigny, France, ¹⁹Pulmonology department, Avicenne Hospital, Bobigny, France, ²⁰Hopital Bichat, Paris University, Paris, France, ²¹Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with RA. To date, there are no specific treatments available…
Abstract Number: 1238 • ACR Convergence 2022
Can Thermal Imaging Help Clarify Joint Inflammation at Clinically Quiescent Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis?
York Kiat Tan, Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore
Background/Purpose: Ultrasound (US) is superior to clinical examination and can be used for more accurate assessment of joint inflammation in rheumatoid arthritis (RA). However, it…
Abstract Number: 1351 • ACR Convergence 2022
Development, Implementation, and Usability Testing of a New Rheumatoid Arthritis Patient-Reported Outcomes EHR-based Dashboard: A Mixed-Method Study
Cammie Young¹, Anna Montgomery², Catherine Nasrallah³, Lindsay Jacobsohn⁴, Jennifer Barton⁵, Sara Murray⁴, Jinoos Yazdany⁶ and Gabriela Schmajuk⁷, ¹University of California San Francisco, San Francisco, CA, ²University of California, San Francisco, USA; San Francisco VA Medical Center, San Francisco, USA, San Francisco, CA, ³UCSF, San Francisco, ⁴University of California, San Francisco, San Francisco, CA, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UCSF, San Francisco, CA, ⁷UCSF / SFVA, San Francisco, CA
Background/Purpose: Shared decision making is a key component of a treat-to-target approach for the treatment of rheumatoid arthritis (RA). We created an EHR tool that…
Abstract Number: 1399 • ACR Convergence 2022
Inflammatory Arthritis Genetic Risk Factors to Predict Treatment Patterns in Rheumatoid Arthritis
Gregory McDermott¹, Jing Cui¹, Rachel Knevel², Kumar Dahal¹, Dana Weisenfeld¹, Priyam Das³, Elizabeth Karlson¹, Su-Chun Cheng⁴, Soumya Raychaudhuri¹, Tianxi Cai⁴ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Leiden University Medical Center, Leiden, Netherlands, ³Harvard Medical School, Boston, MA, ⁴Harvard TH Chan School of Public Health, Boston, MA
Background/Purpose: In a prior study, we described an alternative method for subphenotyping RA patients by the sequence of biologic DMARDs (bDMARDs) they receive over time.…
Abstract Number: 1415 • ACR Convergence 2022
Different Bioactive Lipid Profile Predicts Response to TNF or IL6 Inhibitors in Rheumatoid Arthritis: Result of the CorEvitas CERTAIN Comparative Effectiveness Study
Mona Alotaibi¹, Roxana Coras², Dimitrios Pappas³, Ted Mikuls⁴, Joel Kremer⁵, Geoffrey Thiele⁶, mohit jain¹ and Monica Guma⁷, ¹Department of Medicine, School of Medicine, University of California San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³CorEvitas, LLC, Waltham, MA, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁵The Corrona Research Foundation, Delray Beach, FL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷UCSD, La Jolla, CA
Background/Purpose: Circulating bioactive lipids can provide information about the pathogenesis of specific diseases and potentially help predict therapeutic response. Choosing the right biological therapy earlier…
Abstract Number: 1435 • ACR Convergence 2022
Effectiveness of Combination Therapy with Tocilizumab and Low-Dose Prednisolone as an Induction Therapy in Biologics-Naïve Patients with Rheumatoid Arthritis: A Prospective, Randomized, Controlled, Open-Label, Multicenter Study
Kazuhiro Yokota¹, Hayato Nagasawa², Yuji Akiyama³ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, ²Nagasawa Clinic, Kawagoe, Japan, ³Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Iruma Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: Efficacy and safety of tocilizumab (TCZ) in the treatment of rheumatoid arthritis (RA) has demonstrated in randomized controlled trials. However, the clinical response to…
Abstract Number: 1613 • ACR Convergence 2022
Diagnostic Delay and Less Intensive Therapy for People with Psoriatic Arthritis Compared with Rheumatoid Arthritis: A Nested Matched Cohort Study from Within the UK National Early Inflammatory Arthritis Audit
Rachel Charlton¹, Laura Coates², James Galloway³, Neil McHugh¹, Anita McGrogan¹, Simon Hackett⁴, Melanie Brooke⁵ and William Tillett⁶, ¹University of Bath, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³King's College London, London, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵Bath Institute for Rheumatic Disease, Bath, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: To compare the time from symptom onset and General Practitioner (GP) presentation to referral and diagnosis for patients with psoriatic arthritis (PsA) to those…
Abstract Number: 1735 • ACR Convergence 2022
Clonally Expanded Cytotoxic CD8+ T Cells Recognize Citrullinated Antigens in ACPA+ Rheumatoid Arthritis
Jae-Seung Moon¹, Shady Younis², Orr Sharpe², Navin Rao³, Julie Carman³, Eddie James⁴, Jane Buckner⁴, Kevin D Deane⁵, Michael Holers⁶, Laura Donlin⁷, Mark Davis² and William Robinson⁸, ¹Stanford University, Palo Alto, CA, ²Stanford University, Stanford, CA, ³Janssen Research and Development, LLC, Spring House, PA, ⁴Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁵University of Colorado Denver Anschutz Medical Campus, Denver, CO, ⁶Department of Medicine Division of Rheumatology, Aurora, CO, ⁷Hospital for Special Surgery, New York, NY, ⁸Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease associated with MHC polymorphisms. The shared epitope polymorphism in MHC class II genes is by far…
Abstract Number: 1769 • ACR Convergence 2022
Comparative Evaluation of Adverse Events Associated with Subcutaneous Infliximab (CT-P13 SC) and Intravenous Infliximab: A Real-world Analysis of Post-marketing Surveillance Data
Xenofon Baraliakos¹, Diego Kyburz², Jérôme Avouac³, Nick Barkham⁴ and Soohyun Lee⁵, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University Hospital Basel, Basel, Switzerland, ³University of Paris, Paris, France, ⁴New Cross Hospital, Telford, United Kingdom, ⁵Celltrion Healthcare, Incheon, Republic of Korea
Background/Purpose: The first subcutaneous (SC) formulation of infliximab (IFX) received approval for the treatment of rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), ankylosing…
Abstract Number: 1958 • ACR Convergence 2022
The Increased Risk of Staphylococcus Aureus Bacteremia in Rheumatoid Arthritis – What Is the Impact of Glucocorticoids, Biologic Disease-Modifying Anti-Rheumatic Drugs and Disease Activity: A Danish Nationwide Nested Case-Control Study in the DANBIO Registry
Sabine Dieperink¹, Bente Glintborg², Frank Mehnert³, Mette Nørgaard³, Louise Bruun Oestergaard⁴, Thomas Benfield⁵, Christian Torp-Pedersen⁶, Andreas Petersen⁷ and Merete Lund Hetland¹, ¹Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark, ²Rigshospitalet, Glostrup, Virum, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark, ⁵Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark, ⁶Copenhagen University Hospital - North Zealand, Copenhagen, Denmark, ⁷Statens Serum Institut, Copenhagen, Denmark
Background/Purpose: Staphylococcus aureus bacteremia (SAB) has high mortality.[1] We have previously identified an approximately doubled risk in patients with rheumatoid arthritis (RA),[2] but the role…
Abstract Number: 1976 • ACR Convergence 2022
Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019
Amar Suwal¹, Biraj Shrestha², Ibiyemi Oke² and Anthony Donato², ¹Reading Hospital, Tower Health, Reading, PA, ²reading hospital- tower health, Reading, PA
Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions.…
Abstract Number: 1993 • ACR Convergence 2022
Changes in Omega-6- and Omega-3-Derived Bioactive Lipids in Response to an Anti-Inflammatory Dietary Intervention
Esha Lal¹, Marta Sala Climent², francesca cedola², Marta Fernandez-Bustamante³, Meritxell Agustín-Perez², Maram Alharti², Abha Singh⁴, Soo-In Choi², Tania Rivera², Katherine Nguyen⁴, Susan Lee², Aaron Armando⁵, Tiffany Holt⁶, Oswald Quehenberger⁵, Shahrokh Golshan⁶, Roxana Coras⁷ and Monica Guma⁸, ¹Department of Medicine, School of Medicine, University of California, San Diego, San Diego, ²Department of Medicine, School of Medicine, University of California, San Diego, San Diego, CA, ³Department of Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, ⁴University of California, San Diego, San Diego, CA, ⁵Department of Pharmacology, School of Medicine, University of California, San Diego, San Diego, CA, ⁶Department of Psychiatry, School of Medicine, University of California, San Diego, San Diego, CA, ⁷University of California San Diego, San Diego, CA, ⁸UCSD, La Jolla, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes joint pain, swelling, stiffness, and decreased mobility. Despite the various treatment options for RA, many…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].